Free tool
FAERS Monitor: Rocuronium Bromide
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219108 or its brand name (Rocuronium Bromide, Rocuronium Bromide). Reports on generic versions are filed under their own applications.
Reports
5,786
Serious
5,018
87% of reports
Hospitalization
1,794
Death reported
441
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaphylactic shock693
- drug ineffective690
- anaphylactic reaction618
- hypotension519
- cardiac arrest355
- tachycardia214
- bronchospasm212
- bradycardia197
- rash182
- drug interaction168
- urticaria159
- off label use157
- oxygen saturation decreased144
- respiratory failure129
- blood pressure decreased125
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 51 |
| 2006 | 36 |
| 2007 | 55 |
| 2008 | 107 |
| 2009 | 177 |
| 2010 | 196 |
| 2011 | 267 |
| 2012 | 270 |
| 2013 | 116 |
| 2014 | 150 |
| 2015 | 138 |
| 2016 | 263 |
| 2017 | 209 |
| 2018 | 272 |
| 2019 | 375 |
| 2020 | 314 |
| 2021 | 303 |
| 2022 | 415 |
| 2023 | 487 |
| 2024 | 459 |
| 2025 | 542 |
| 2026 | 566 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,373 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic shockSignal | 693 | 100.4 | 93.5 | 66,358 |
| bronchospasmSignal | 212 | 54.8 | 48.0 | 10,985 |
| anaphylactic reactionSignal | 618 | 41.1 | 38.1 | 23,935 |
| cardiac arrestSignal | 355 | 15.7 | 14.2 | 4,867 |
| bradycardiaSignal | 197 | 13.6 | 11.8 | 2,275 |
| hypotensionSignal | 519 | 9.4 | 8.7 | 3,929 |
| oxygen saturation decreasedSignal | 144 | 9.3 | 7.9 | 1,064 |
| tachycardiaSignal | 214 | 8.8 | 7.7 | 1,469 |
| blood pressure decreasedSignal | 125 | 6.8 | 5.8 | 619 |
| respiratory failureSignal | 129 | 6.4 | 5.4 | 588 |
| drug interactionSignal | 168 | 3.9 | 3.3 | 354 |
| urticariaSignal | 159 | 3.5 | 3.0 | 276 |
| drug ineffective | 690 | 1.9 | 1.8 | 315 |
| rash | 182 | 1.5 | 1.3 | 32 |
| off label use | 157 | 0.7 | 0.6 | 30 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.